This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Endometrial carcinoma and HRT

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Studies have shown that unopposed oestrogen increases the risk of both endometrial hyperplasia and of endometrial endometrial carcinoma - by a factor of eight. The effects are usually apparent 2 years after treatment.).

However, it has been shown that the inclusion of 7-10 days of progestagen in the 28 day cycle reduces the increased risk; however the addition of progestogen does not eliminate the risk of endometrial cancer associated with HRT use (1).Observational studies suggest that there are about 20 extra cases of endometrial cancer per 1000 women treated with oestrogen-progestogen combination, compared with the estimate of 42 extra cases of endometrial cancer with oestrogen-only therapy (1).

The MHRA has summarised the risks of HRT with respect to breast, endometrial and ovarian cancer (2):

Summary of HRT risks and benefits* during current use and current use plus post-treatment from age of menopause up to age 69 years, per 1000 women with 5 years or 10 years use of HRT (2)

 

Reference:

  1. Current Problems in Pharmacovigilance (2002), 28, 1-3.
  2. MHRA (August 2019). Hormone replacement therapy and risk of breast cancer

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.